C4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
The company’s subsidiary C4X Discovery Ltd got €7m upfront with potential to gain €414m in total for the global commercialisation rights for its preclinical C4XD oral IL-17A inhibitor programme. Under the terms of the agreement, C4XD could receive €11m in pre-clinical milestones, in addition to single digit royalties.
Under the license, Sanofi will develop and commercialise an oral therapy for the treatment of chronci inflammatory diseases, a multi-billion dollar market. The IL-17 family of cytokines are strong inducers of inflammation and are implicated in a variety of autoimmune diseases including psoriasis, psoriatic arthritis and ankylosing spondylitis. Current treatments targeting IL-17 are monoclonal antibodies administered by injection. The company believed that ab oral small molecule therapy might increase therapy compliance. C
According to Clive Dix, CEO of C4X Discovery,the psoriasis market alone is estimated to be worth US$24bn per annum by 2027,
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://european-biotechnology.com/up-to-date/latest-news/news/c4x-discovery-and-sanofi-ink-eur414m-il-17a-blocker-rd-contract.html